Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 7244Neoplasms 4539Prostatic Neoplasms 3489Colorectal Neoplasms 2940Carcinoma, Non-Small-Cell Lung 2831Lung Neoplasms 2547Leukemia, Myeloid, Acute 1982Pancreatic Neoplasms 1874Multiple Myeloma 1811Carcinoma, Hepatocellular 1733Neoplasm Metastasis 1585Stomach Neoplasms 1502Lymphoma 1457Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Head and Neck Neoplasms 1435Brain Neoplasms 1373Melanoma 1348Ovarian Neoplasms 1342Leukemia 1303Rectal Neoplasms 1270Recurrence 1255Colonic Neoplasms 1204Glioblastoma 1138Uterine Cervical Neoplasms 1096Lymphoma, Non-Hodgkin 1066Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 932Squamous Cell Carcinoma of Head and Neck 921

Interventions

fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Interventional × Female Breast Cancer Patients × Clear all
NCT06254066 2024-02-12

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
40 enrolled
Breast

Female Breast Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡